TREATMENT OF CARDIOMYOPATHY THROUGH MODULATION OF HYPOXIA-INDUCED eRNA ACTIVITY
AssigneeUnited Kingdom Research and Innovation
InventorJaya KRISHNAN
Life of this patent
Estimating the term…
Abstract
The invention relates to an inhibitor, in particular an antisense oligonucleotide, directed against the enhancer RNA SINT1 for use in a method for the prevention or treatment of heart disease, particularly for cardiomyopathy. The antisense oligonucleotide is a gapmer or RNA interference (RNAi) agent. The antisense oligonucleotide is particularly suitable for the treatment of cardiomyopathy resulting from cardiac overload.
Claims15
A method for the inhibition or treatment of heart disease, particularly cardiomyopathy, comprising administering to a patient in need thereof a therapeutically effective amount of an oligonucleic acid agent directed at and capable of specifically inhibiting and/or degrading the enhancer RNA SINT1 (SEQ ID NO 001).
(canceled)
An oligonucleotide agent directed against the enhancer RNA SINT1 (SEQ ID No 001) that comprises or consists of any one of the sequence of SEQ ID NO 060 to SEQ ID NO 202, in particular sequences of SEQ ID NO 060 to SEQ ID NO 069.
Dependencies are inferred from the claim text.